(Q50584552)

English

Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.

scientific article published in June 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone. (English)

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

Geneviève Chêne

12

object named as

Geneviève Chêne

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

author name string

Victor de Lédinghen

1

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

Pascale Trimoulet

2

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

Maria Winnock

3

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

Pierre-Henri Bernard

4

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

Marc Bourlière

5

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

Isabelle Portal

6

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

André-Jean Rémy

7

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

Nathalie Szostak

8

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

Stéphane Lévy

9

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

Albert Tran

10

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

Armand Abergel

11

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

Hervé Fleury

13

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

Patrice Couzigou

14

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

French Multicenter Study Group

15

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

publication date

1 June 2002

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

Journal of Hepatology

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

36

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

819-826

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

6

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical Pharmacokinetics of Interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900071-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0168-8278(02)00071-5

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/12044534

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50584552&oldid=1540640745"